

Regimen Reference Order – GENU - apalutamide

ARIA: - GENU – [apalutamide]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)
Indication for Use: Prostate Cancer, Non-metastatic castration-resistant

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – GENU - apalutamide

Drug	Dose	CCMB Administration Guideline
apalutamide	240 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
apalutamide (Erleada®) available dosage strength: 60 mg tablets		
Classification: Non-Cytotoxic, Hazardous		

REQUIRED MONITORING

Baseline

- CBC , biochemistry, electrolytes, serum creatinine, TSH, testosterone and PSA
- EKG for those on anti-arrhythmics at physician's discretion
- Blood pressure

Subsequent Treatment

- CBC , biochemistry, serum creatinine, TSH monthly
- PSA monthly for 3 months, then every 3 months as per Physician Orders
- Blood pressure every 2 weeks for 3 months and then as required

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- Inform patient to report rash or uncontrolled diarrhea

ADDITIONAL INFORMATION

- LHRH analog treatment is continued during apalutamide treatment
- Patients are at increased fracture risk
- apalutamide has been associated with seizures